Opportunity Information: Apply for PAR 23 106
Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional) (PAR-23-106) is an NIH grant opportunity designed to spur new, early-stage HIV/AIDS research that directly fits within the National Institute on Deafness and Other Communication Disorders (NIDCD) mission. In practical terms, the FOA is looking for projects that connect HIV/AIDS to conditions, mechanisms, interventions, or outcomes related to hearing, balance (vestibular function), taste, smell, voice, speech, or language. The emphasis is on advancing knowledge and generating promising preliminary data in these communication-disorder domains, rather than funding large, definitive studies.
A central requirement is that proposed aims should align with the high-priority HIV/AIDS research areas identified by the NIH Office of AIDS Research (OAR). Applicants are expected to use the OAR HIV/AIDS research priorities as a guiding framework when describing significance, innovation, and how the work fills a recognized gap in the broader HIV/AIDS research landscape. The FOA therefore sits at the intersection of two needs: (1) NIH-wide HIV/AIDS priorities and (2) NIDCD-specific scientific areas involving sensory and communication functions. Competitive applications will make that intersection explicit, explaining why the HIV/AIDS component is essential to the question being asked and why NIDCD-relevant outcomes or mechanisms are the right lens for addressing it.
The award mechanism is the NIH R21, which is commonly used for exploratory or developmental research. R21 projects typically focus on high-impact ideas that may still be at an early stage, including new hypotheses, novel tools or measures, pilot human studies, or proof-of-concept work that can position a team for later, larger-scale research. While the FOA allows clinical trials, it limits support to low-risk clinical trials only. That means applicants considering a clinical trial component should plan for minimal-risk interventions and procedures, clear monitoring, and a design that is appropriate for an exploratory grant rather than a full efficacy trial.
Eligibility is broad and includes many types of domestic applicants that commonly apply to NIH grants, such as public and private institutions of higher education, state and local governments, federally recognized Native American tribal governments, tribal organizations, nonprofits with and without 501(c)(3) status, public housing authorities/Indian housing authorities, for-profit organizations (including those that are not small businesses), and small businesses. The FOA also highlights additional eligible applicant types and community-centered institutions and entities, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. (foreign) organizations. This wide eligibility is important because HIV/AIDS-related communication and sensory health questions often require partnerships across academic, clinical, public health, and community settings, and may benefit from work in diverse populations and global contexts.
From an administrative standpoint, this is a discretionary grant opportunity in the health category administered by the National Institutes of Health, with CFDA listing 93.173. The opportunity was created on February 14, 2023, and the listed closing date is January 7, 2026. The award ceiling and expected number of awards are not specified in the provided source details, which typically means applicants should consult the full FOA and NIH guidance for budget expectations, project period norms, and any institute-specific constraints.
Overall, the FOA is a targeted invitation for investigators to bring strong HIV/AIDS-relevant questions into NIDCD mission areas, especially where HIV infection, treatment, comorbidities, or related social and biological factors may influence communication and sensory systems. The best-fit proposals are likely to be those that clearly justify why the work is HIV/AIDS research (not simply tangential), clearly justify why NIDCD-relevant outcomes are central to the aims, and propose a feasible exploratory plan that can meaningfully move the field forward, including (where applicable) a well-justified low-risk clinical trial design.Apply for PAR 23 106
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173.
- This funding opportunity was created on 2023-02-14.
- Applicants must submit their applications by 2026-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional) (PAR-23-106) is an NIH grant opportunity intended to stimulate new, early-stage HIV/AIDS research that directly fits within the mission of the National Institute on Deafness and Other Communication Disorders (NIDCD). It is built to support exploratory or developmental projects rather than large, definitive studies.
Which NIH institute is leading this opportunity?
The opportunity is administered by the National Institutes of Health (NIH) and is specifically tied to the mission areas of the National Institute on Deafness and Other Communication Disorders (NIDCD).
What kinds of scientific topics are a good fit?
Projects should connect HIV/AIDS to conditions, mechanisms, interventions, or outcomes related to NIDCD mission domains: hearing, balance (vestibular function), taste, smell, voice, speech, or language. Strong applications make the HIV/AIDS component essential to the research question and make NIDCD-relevant outcomes or mechanisms central to the aims.
Does my project need to be explicitly HIV/AIDS research?
Yes. Competitive projects are expected to clearly justify why the work is truly HIV/AIDS research rather than a topic where HIV/AIDS is only incidental or tangential. The application should make it obvious why HIV infection, treatment, comorbidities, or related biological and social factors are integral to the question being asked.
How should applicants use the NIH Office of AIDS Research (OAR) priorities?
Proposed aims should align with the high-priority HIV/AIDS research areas identified by the NIH Office of AIDS Research (OAR). Applicants are expected to use OAR priorities as a guiding framework when describing significance, innovation, and how the project fills a recognized gap in the broader HIV/AIDS research landscape.
What grant mechanism is used for this opportunity?
This FOA uses the NIH R21 mechanism, which is commonly used for exploratory or developmental research. R21 projects are generally designed to advance high-impact ideas that are still early stage, including pilot work and proof-of-concept studies.
What is the intended scope of an R21 project under this FOA?
The emphasis is on advancing knowledge and generating promising preliminary data in communication-disorder and sensory domains relevant to NIDCD (hearing, balance, taste, smell, voice, speech, language) in the context of HIV/AIDS. It is not positioned as a mechanism for large, definitive studies.
Are clinical trials allowed?
Yes. The FOA is clinical trial optional, meaning clinical trials may be proposed.
If I propose a clinical trial, are there restrictions?
Yes. The FOA limits support to low-risk clinical trials only. Applicants considering a clinical trial should plan for minimal-risk interventions and procedures, clear monitoring, and an exploratory design appropriate for an R21 rather than a full-scale efficacy trial.
What does "low-risk clinical trial" imply in this FOA context?
Based on the provided information, it implies minimal-risk interventions and procedures, appropriate monitoring, and an approach consistent with exploratory research (for example, pilot or proof-of-concept work) rather than a definitive, large-scale trial.
Who is eligible to apply?
Eligibility is broad and includes many domestic applicant types commonly eligible for NIH grants, including: public and private institutions of higher education, state and local governments, federally recognized Native American tribal governments, tribal organizations, nonprofits with and without 501(c)(3) status, public housing authorities/Indian housing authorities, for-profit organizations (including those that are not small businesses), and small businesses.
Are community-centered and minority-serving institutions included in eligible applicants?
Yes. The FOA highlights additional eligible applicant types and community-centered institutions and entities, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and faith-based or community-based organizations.
Can federal agencies apply?
Yes. Eligible federal agencies are listed among the highlighted eligible applicant types.
Can organizations in U.S. territories or possessions apply?
Yes. Regional organizations and U.S. territories or possessions are listed among eligible applicant types.
Are non-U.S. (foreign) organizations eligible?
Yes. The FOA explicitly includes non-U.S. (foreign) organizations among eligible applicants.
Why is the eligibility scope so broad for this FOA?
The FOA notes that HIV/AIDS-related communication and sensory health questions often require partnerships across academic, clinical, public health, and community settings, and may benefit from work in diverse populations and global contexts.
What is the CFDA number for this opportunity?
The CFDA listing provided is 93.173.
What is the opportunity type and category?
It is described as a discretionary grant opportunity in the health category administered by NIH.
When was this opportunity created?
The opportunity was created on February 14, 2023.
What is the closing date listed for this opportunity?
The listed closing date is January 7, 2026.
Is the maximum award amount (award ceiling) provided?
No. The award ceiling is not specified in the provided information, which suggests applicants should consult the full FOA and NIH guidance for budget expectations and any institute-specific constraints.
Is the expected number of awards provided?
No. The expected number of awards is not specified in the provided information.
What makes an application competitive for this FOA?
Based on the description provided, competitive applications typically (1) make the intersection between NIH-wide HIV/AIDS priorities and NIDCD mission areas explicit, (2) explain why the HIV/AIDS component is essential to the research question, (3) explain why NIDCD-relevant outcomes or mechanisms are the right lens, and (4) propose a feasible exploratory plan that can generate meaningful preliminary data, including a well-justified low-risk clinical trial design if a trial is included.
What kinds of outcomes or domains should be central to the aims?
The aims should focus on NIDCD-relevant outcomes or mechanisms tied to communication and sensory systems: hearing, balance (vestibular), taste, smell, voice, speech, or language, in a way that is meaningfully connected to HIV/AIDS.
Is this FOA intended for large, definitive studies?
No. The FOA emphasizes early-stage, exploratory research intended to advance knowledge and generate promising preliminary data, rather than supporting large, definitive studies.
Browse more opportunities from the same category: Health
Next opportunity: BJA FY 23 Tribal Justice Training and Technical Assistance Program
Previous opportunity: FY23 IIJA Bureau of Land Management Nevada (NV) Environmental Quality and Protection
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 106
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 106) also looked into and applied for these:
| Funding Opportunity |
|---|
| Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional) Apply for RFA MD 23 004 Funding Number: RFA MD 23 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| AHRQ Improving Diagnostic Safety in Ambulatory Care: Strategies and Preventions (R18) Apply for RFA HS 23 011 Funding Number: RFA HS 23 011 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Dissemination and Implementation of Equity-Focused Evidence-Based Interventions in Healthcare Delivery Systems (R18) Apply for RFA HS 23 002 Funding Number: RFA HS 23 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $2,500,000 |
| AHRQ Understanding and Improving Diagnostic Safety in Ambulatory Care: Incidence and Contributing Factors (R01) Apply for RFA HS 23 010 Funding Number: RFA HS 23 010 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Supporting the Management of Substance Use Disorders in Primary Care and other Ambulatory Settings (R18) Apply for RFA HS 23 005 Funding Number: RFA HS 23 005 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $625,000 |
| Genomics Centers for Infectious Diseases (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 015 Funding Number: RFA AI 23 015 Agency: National Institutes of Health Category: Health Funding Amount: $2,850,000 |
| Using Secondary Data Analysis to Determine Whether Preventive Interventions Implemented Earlier in Life Reduce Suicide Risk (U01 Clinical Trial Not Allowed) Apply for RFA MH 23 275 Funding Number: RFA MH 23 275 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional) Apply for RFA AT 24 001 Funding Number: RFA AT 24 001 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed) Apply for RFA AG 24 014 Funding Number: RFA AG 24 014 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required) Apply for RFA AG 24 015 Funding Number: RFA AG 24 015 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| NIMH Short Courses for Mental Health Related Research (R25 -Independent Clinical Trial Not Allowed) Apply for PAR 23 265 Funding Number: PAR 23 265 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIMH Mentoring Networks for Mental Health Research Education (R25 Clinical Trial Not Allowed) Apply for PAR 23 263 Funding Number: PAR 23 263 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIMH Research Education Programs for Psychiatry Residents (R25- Independent Clinical Trial Not Allowed) Apply for PAR 23 266 Funding Number: PAR 23 266 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Roybal Centers for Translational Behavioral Research on Dementia Care, Caregiver Support, and Prevention of Alzheimers Disease and Related Dementias (AD/ADRD) (P30 Clinical Trial Required) Apply for RFA AG 24 007 Funding Number: RFA AG 24 007 Agency: National Institutes of Health Category: Health Funding Amount: $750,000 |
| Edward R. Roybal Coordinating Center (R24 - Clinical Trial Not Allowed) Apply for RFA AG 24 008 Funding Number: RFA AG 24 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Roybal Centers for Translational Research on Aging (P30 Clinical Trial Required) Apply for RFA AG 24 006 Funding Number: RFA AG 24 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Biomedical Technology Optimization and Dissemination Center (BTOD)(RM1-Clinical Trial Not Allowed) Apply for PAR 23 110 Funding Number: PAR 23 110 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Coordination Center for the Models of Infectious Disease Agent Study (MIDAS) Program (R24 Clinical Trial Not Allowed) Apply for PAR 23 129 Funding Number: PAR 23 129 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| National Centers for Cryoelectron Microscopy (R24 Clinical Trial Not Allowed) Apply for PAR 23 118 Funding Number: PAR 23 118 Agency: National Institutes of Health Category: Health Funding Amount: $6,500,000 |
| Limited Competition: Small Grant Program for ORIP Special Emphasis Research Career Award (SERCA) K01 Recipients (R03 Clinical Trials Not Allowed) Apply for PAR 23 127 Funding Number: PAR 23 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 106", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.